Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats
| Autor: | Victor P Bilan, Simon M. Poucher, Eman M. Salah, Bradley Zinker, Rachel M. Mayers, Sheldon I. Bastacky, Stevan P. Tofovic, Huw B. Jones |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Renal Hypertrophy Endocrinology Diabetes and Metabolism Angiotensin-Converting Enzyme Inhibitors Blood Pressure Kidney urologic and male genital diseases Rosiglitazone Diabetic nephropathy Endocrinology Enalapril Diabetes mellitus Internal medicine Animals Humans Hypoglycemic Agents Medicine Glucose homeostasis Diabetic Nephropathies Obesity Antihypertensive Agents Metabolic Syndrome business.industry Myocardium Body Weight Glomerulosclerosis medicine.disease Rats PPAR gamma Disease Models Animal Liver Thiazolidinediones Metabolic syndrome business medicine.drug |
| Zdroj: | Journal of Endocrinology. 210:293-308 |
| ISSN: | 1479-6805 0022-0795 |
| DOI: | 10.1530/joe-11-0122 |
| Popis: | Diabetic nephropathy (DN) is a major cause of end-stage renal disease. Yet the pathogenic mechanisms underlying the development of DN are not fully defined, partially due to lack of suitable models that mimic the complex pathogenesis of renal disease in diabetic patients. In this study, we describe early and late renal manifestations of DN and renal responses to long-term treatments with rosiglitazone or high-dose enalapril in ZSF1 rats, a model of metabolic syndrome, diabetes, and chronic renal disease. At 8 weeks of age, obese ZSF1 rats developed metabolic syndrome and diabetes (hyperglycemia, glucosuria, hyperlipidemia, and hypertension) and early signs of renal disease (proteinuria, glomerular collagen IV deposition, tubulointerstitial inflammation, and renal hypertrophy). By 32 weeks of age, animals developed renal histopathology consistent with DN, including mesangial expansion, glomerulosclerosis, tubulointerstitial inflammation and fibrosis, tubular dilation and atrophy, and arteriolar thickening. Rosiglitazone markedly increased body weight but reduced food intake, improved glucose control, and attenuated hyperlipidemia and liver and kidney injury. In contrast, rosiglitazone markedly increased cardiac hypertrophy via a blood pressure-independent mechanism. High-dose enalapril did not improve glucose homeostasis, but normalized blood pressure, and nearly prevented diabetic renal injury. The ZSF1 model thus detects the clinical observations seen with rosiglitazone and enalapril in terms of primary and secondary endpoints of cardiac and renal effects. This and previous reports indicate that the obese ZSF1 rat meets currently accepted criteria for progressive experimental diabetic renal disease in rodents, suggesting that this may be the best available rat model for simulation of human DN. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|